ES2167373T3 - Un metodo para la sensibilizacion de celulas cancerosas con respecto a la lisis mediada por celulas asesinas. - Google Patents

Un metodo para la sensibilizacion de celulas cancerosas con respecto a la lisis mediada por celulas asesinas.

Info

Publication number
ES2167373T3
ES2167373T3 ES94922877T ES94922877T ES2167373T3 ES 2167373 T3 ES2167373 T3 ES 2167373T3 ES 94922877 T ES94922877 T ES 94922877T ES 94922877 T ES94922877 T ES 94922877T ES 2167373 T3 ES2167373 T3 ES 2167373T3
Authority
ES
Spain
Prior art keywords
cells
lisis
murder
sensitization
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94922877T
Other languages
English (en)
Inventor
Edward Baral
Istvan Berczi
Eva Nagy
Lauri Kangas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Application granted granted Critical
Publication of ES2167373T3 publication Critical patent/ES2167373T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A UN METODO PARA SENSIBILIZAR LAS CELULAS CANCERIGENAS PARA LA LISIS INTERMEDIADA POR CELULAS ASESINAS QUE COMPRENDE LA ADMINISTRACION A UN PACIENTE DE UNA CANTIDAD EFECTIVA DE UN ANTIESTROGENO Y DE CELULAS ASESINAS, TANTO JUNTOS COMO SECUENCIALMENTE, EN DONDE LAS CELULAS ASESINAS SE SELECCIONAN ENTRE EL GRUPO DE CELULAS NK, CELULAS LAK Y CELULAS CTL Y EL ANTIESTROGENO SE SELECCIONA ENTRE EL GRUPO DE LOS ANTIESTROGENOS DE LA CLASE DEL TRIFENILETILENO, COMO EL TAMOXIFEN O EL TOREMIFENO O SUS SALES FARMACOLOGICAMENTE ACEPTABLES.
ES94922877T 1993-08-09 1994-08-02 Un metodo para la sensibilizacion de celulas cancerosas con respecto a la lisis mediada por celulas asesinas. Expired - Lifetime ES2167373T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10351993A 1993-08-09 1993-08-09

Publications (1)

Publication Number Publication Date
ES2167373T3 true ES2167373T3 (es) 2002-05-16

Family

ID=22295643

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94922877T Expired - Lifetime ES2167373T3 (es) 1993-08-09 1994-08-02 Un metodo para la sensibilizacion de celulas cancerosas con respecto a la lisis mediada por celulas asesinas.

Country Status (16)

Country Link
US (1) US5788964A (es)
EP (1) EP0726772B1 (es)
JP (1) JPH09501174A (es)
KR (1) KR100340091B1 (es)
AT (1) ATE208207T1 (es)
AU (1) AU693459B2 (es)
CA (1) CA2168584C (es)
CZ (1) CZ285508B6 (es)
DE (1) DE69429011T2 (es)
ES (1) ES2167373T3 (es)
HU (1) HUT74425A (es)
NO (1) NO316823B1 (es)
NZ (1) NZ269149A (es)
RU (1) RU2153332C2 (es)
SK (1) SK283124B6 (es)
WO (1) WO1995004544A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
HU223344B1 (hu) * 1997-08-13 2004-06-28 Máté Hidvégi Immunstimuláns és metasztázist gátló fermentált, szárított anyag, ezt tartalmazó gyógyszerkészítmények, eljárás az előállítására és alkalmazásai
US6413534B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
SI1003496T1 (en) 1998-05-07 2005-10-31 The University Of Tennessee Research Corporation Medicament for treating prostate intraepithelial neoplasia
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
EP1372717A2 (en) * 2001-03-23 2004-01-02 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
EP1416964A4 (en) * 2001-07-09 2005-10-12 Aphton Corp TREATMENT AND PREVENTION OF CANCER AND PRECANCEROUS DISEASES OF THE LIVER, LUNG AND ESOPHAGUS
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US6555095B1 (en) 2001-12-14 2003-04-29 Avon Products, Inc. Topical compositions and methods of application
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
EP1608984A2 (en) * 2003-03-28 2005-12-28 Aphton Corporation Gastrin hormone immunoassays
AU2004261260B2 (en) * 2003-08-01 2011-01-27 A & G Pharmaceuticals, Inc. Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
CA2580965C (en) 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
WO2011096534A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
CA2971216A1 (en) 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024833A (en) * 1988-03-10 1991-06-18 Industrial Farmaceutica Serono Spa Combined interferon/antiestrogen therapy for treatment of breast cancer
US5057423A (en) * 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
EP0589039A1 (en) * 1991-04-30 1994-03-30 Asahi Kasei Kogyo Kabushiki Kaisha Triphenylethylene derivative and pharmaceutical preparation containing the same

Also Published As

Publication number Publication date
US5788964A (en) 1998-08-04
AU693459B2 (en) 1998-07-02
AU7263794A (en) 1995-02-28
SK283124B6 (sk) 2003-02-04
EP0726772B1 (en) 2001-11-07
NO960511D0 (no) 1996-02-08
NO960511L (no) 1996-02-08
RU2153332C2 (ru) 2000-07-27
DE69429011D1 (de) 2001-12-13
ATE208207T1 (de) 2001-11-15
HU9600294D0 (en) 1996-04-29
CA2168584A1 (en) 1995-02-16
JPH09501174A (ja) 1997-02-04
EP0726772A1 (en) 1996-08-21
KR960703616A (ko) 1996-08-31
SK18096A3 (en) 1996-11-06
KR100340091B1 (ko) 2002-09-27
CA2168584C (en) 2008-10-14
NO316823B1 (no) 2004-05-24
DE69429011T2 (de) 2002-07-11
NZ269149A (en) 1997-06-24
HUT74425A (en) 1996-12-30
WO1995004544A1 (en) 1995-02-16
CZ285508B6 (cs) 1999-08-11
CZ31696A3 (en) 1997-03-12

Similar Documents

Publication Publication Date Title
ES2167373T3 (es) Un metodo para la sensibilizacion de celulas cancerosas con respecto a la lisis mediada por celulas asesinas.
CO2021005774A2 (es) Lípidos con amina ionizables
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
DOP2022000115A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
PA8570701A1 (es) Compuestos que modulan la actividad de ppar y procedimientos para su preparacion
PA8577101A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
PA8592301A1 (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
PA8592201A1 (es) Nuevos derivados de fluoroglicosidos aromaticos, medicamentos que contienen estos compuestos y sus usos
UY31068A1 (es) Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570
ECSP055613A (es) Derivados de pirimidina y su uso como moduladores cb2
UY28876A1 (es) Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central
GT198500081A (es) Azolil-(1)-metanos y sus sales, procedimientos para su pro--duccion, asi como su aplicacion como medicamentos.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
UY29181A1 (es) Derivados de bencenosulfonamidas n-sustituidos, composiciones que los contienen, procesos de preparación y aplicaciones
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
DOP2020000160A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
UY29790A1 (es) Sales de diariloimidazola-4-carboxamidas, composiciones que las contienen, procesos de preparación y aplicaciones
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
ES2181130T3 (es) Antagonistas quinazolin-4-ona del ampa.
BR112022016012A2 (pt) Produto adesivo à base de polímeros naturais
CL2021000329A1 (es) Compuestos útiles en terapia del vih
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CO2023015212A2 (es) Receptores quiméricos dirigidos a adgre2 y/o clec12a y usos de estos